文献速递心境障碍精神分裂症与精神病性障碍

致幻剂与NMDAR调节剂协同治疗神经精神障碍的假说

Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders.
PubMed 文献 · Mol Psychiatry · 2023-11-09

该文提出假说:将血清素能致幻剂与NMDAR调节剂同步给药,可能增强各自疗效并改善安全性。致幻剂通过5HT2AR激活及与谷氨酸能系统交互增强神经可塑性,NMDAR拮抗剂(如氯胺酮)及甘氨酸位点激动剂(D-丝氨酸、D-环丝氨酸)共享部分机制并具神经可塑性和抗抑郁效应。作者建议首先聚焦于抑郁障碍中裸盖菇素与D-丝氨酸或D-环丝氨酸的急性同步给药研究。

要点

  • 致幻剂与NMDAR调节剂共享5HT2AR-谷氨酸能神经可塑性机制。
  • 同步给药假说旨在增强疗效、允许剂量调整并提高安全性。
  • 建议优先研究抑郁障碍中裸盖菇素与D-丝氨酸或D-环丝氨酸联用。

核心结论

  • 同步给予致幻剂与NMDAR调节剂可能增强各自治疗效应并改善安全性。

研究设计与样本

  • 本文为假说性文章,未报告原始研究设计或样本量。

主要发现

  • 致幻剂通过5HT2AR激活及与离子型谷氨酸受体、TrkB和mTOR的复杂交互增强神经可塑性。
  • 氯胺酮及D-丝氨酸、D-环丝氨酸共享部分神经可塑性和抗抑郁机制。
  • D-丝氨酸和D-环丝氨酸已有促认知效应报告。
  • 5HT2AR-NMDAR交互调节前额叶皮层神经元兴奋性,是新抗精神病药的靶点。

临床怎么用

  • 建议首先在抑郁障碍中开展裸盖菇素与D-丝氨酸或D-环丝氨酸急性同步给药的研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Modern research data suggest a therapeutic role for serotonergic psychedelics in depression and other neuropsychiatric disorders, although psychotomimetic effects may limit their widespread utilization. Serotonergic psychedelics enhance neuroplasticity via serotonin 2 A receptors (5HT2AR) activation and complex serotonergic-glutamatergic interactions involving the ionotropic glutamate receptors, tropomyosin receptor kinase B (TrkB) and the mammalian target of rapamycin (mTOR). N-methyl-d-aspartate receptors (NMDAR) channel antagonists, i.e. ketamine, and glycine modulatory site full and partial agonists, i.e., D-serine (DSR) and D-cycloserine (DCS), share some of these mechanisms of action and have neuroplastic and antidepressant effects. Moreover, procognitive effects have been reported for DSR and DCS and 5HT2AR-NMDAR interactions modulate neuronal excitability in prefrontal cortex and represent a target for new antipsychotics. We hypothesize that the synchronous administration of a psychedelic and a NMDAR modulator may increase the therapeutic impact of each of the treatment components and allow for dose adjustments and improved safety. We propose to initially focus research on the acute concurrent administration of psilocybin and DSR or DCS in depression.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Heresco-Levy U, Lerer B. Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders. Mol Psychiatry. 2023. PMID: 37945694. doi:10.1038/s41380-023-02312-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。